Illumina, Inc. vs Western Union Co — how do they compare? Illumina, Inc. trades at $265 (market cap $40.43B), while Western Union Co trades at $6.32 (market cap $1.91B). The key difference: Illumina, Inc. is far larger — about 21.2× Western Union Co's market cap, and Western Union Co pays a 15.38% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Western Union Co for 95 Days on average.
| ILMN | WU | |
|---|---|---|
Market Cap | $40.43B | $1.91B |
Volume | 2,948,626 | 6,459,194 |
Sector | Health | Financials |
52-Week High | $293.69 | $10.28 |
52-Week Low | $91.00 | $5.90 |
Typical Hold Time | 83 Days | 95 Days |
Enterprise Value | $41.79B | $1.81B |
Dividend Yield | — | 15.38% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Western Union (WU) trades at $6.33, up 3.09% with bearish technical signals but attractive valuation metrics including a P/E of 4.93 and P/S of 0.48. Recent earnings show mixed performance with two misses in the last three quarters, while the company maintains strong profitability with 9.79% net margin and 43.97% ROE. The $200 million Beyond Efficiency Plan and pending Intermex acquisition represent key strategic initiatives amid declining revenue trends from $4.5B in 2022 to $4.0B projected for 2026.
WU presents a value opportunity with deep valuation discounts but faces significant headwinds including revenue contraction and integration risks from the Intermex acquisition. Analyst sentiment remains cautious with only 12% buy ratings, though the $6.86 consensus target offers 8% upside. The stock's appeal hinges on successful cost-cutting execution and digital transformation amid competitive pressures in money transfer services.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →